Law360, New York (February 01, 2012, 1:33 PM ET) -- The Court of Justice of the European Union (CJEU)[1] has ruled in Brustle v. Greenpeace that processes involving the derivation of stem cells from a human embryo at the blastocyst stage, entailing the destruction of that embryo, cannot be patented.
This article briefly sums up the CJEU decision of October 2011 and compares the different approaches to patentability of stem cells being taken in Europe and the U.S. We also consider the implications of these differences on the future of research involving human embryonic stem cells...
The Global Reach Of Stem Cell Research Patents
To view the full article, take a free trial now.
